all report title image

FAST MELT TABLETS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Fast Melt Tablets Market, By Type (Anti Psychotics, Anti Epileptics, CNS Stimulants, Anxiolytics, Anti Parkinsonian Drugs, Anti Hypertensive, NSAIDs, Anti Allergy Drugs, Proton Pump Inhibitors, and Others), By Indication (Pain Management, Allergy and Respiratory Disorders, Neurological Disorders, Gastrointestinal Disorders, Cardiovascular Disorders, and Others), By Dosage Form (Oral, Sublingual, Buccal, and Chewable), By Age Group (Adult, Pediatrics, and Geriatrics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

  • Published In : Jan 2025
  • Code : CMI7726
  • Pages :160
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Fast Melt Tablets Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Key Developments:

  • In December 2022, Melt Pharmaceuticals, Inc., a clinical-stage company, announced Phase 2 results for MELT-300, its lead product for needle- and opioid-free procedural sedation during cataract surgery. MELT-300 is a sublingual tablet combining midazolam (3mg) and ketamine (50mg) using Catalent's Zydis fast-dissolving technology for rapid absorption. The double-blind, placebo-controlled study enrolled over 300 subjects at nine sites to evaluate its efficacy and safety compared to placebo and individual components.
  • Fuji Chemical Industries Co., Ltd.’sv F-MELT is a proprietary excipient designed for producing Fast Melt Tablets (FMTs) and chewable tablets. Ideal for orally disintegrating tablets (ODTs), it enables rapid disintegration in the mouth without water, enhancing patient convenience and compliance. F-MELT supports direct compressibility, allowing easy blending with active pharmaceutical ingredients (APIs) for efficient manufacturing. Its versatility and patient-friendly features make it a leading choice for innovative tablet formulations.

Top Strategies Followed by Global Fast Melt Tablets Market Players

  • Leading pharmaceutical companies are heavily investing in R&D to innovate high-performance Fast Melt Tablets (FMTs)
    • For instance, SPI Pharma has developed proprietary excipients like PharmaBurst 500, Mannogem XL Opal, and Mannogem XL Ruby, which are tailored for orally disintegrating tablets (ODTs), fast-melt, and chewable formulations. These excipients enable rapid disintegration within 30 seconds, enhancing patient compliance and satisfaction.
  • Mid-level players adopt cost-effective strategies to reach price-sensitive groups. Collaborations help strengthen product pipelines and distribution networks. Strategic alliances are crucial for established players to solidify their market presence.
    • For example, forming alliances with major industry players and Original Equipment Manufacturers (OEMs) is a common strategy to solidify market presence. For example, Emisphere Technologies collaborated with a nationally deployed field force and retail pharmacies to launch Eligen B12, the first oral prescription tablet for vitamin B12 deficiency.
  • Emerging manufacturers specialize in niche segments. Expanding global distribution networks is crucial for enhancing market reach. Companies like Rentschler Biopharma have demonstrated this by leveraging their dual-site capabilities across the United States and Europe. This strategic expansion allows them to support a range from clinical development to commercial-scale manufacturing, offering versatile production capacities and meeting diverse market demands

Emerging Startups - Fast Melt Tablets Industry Ecosystem

  • Startups like Melt Pharmaceuticals are developing advanced technologies including smart sensors for monitoring drug delivery. Their innovative approach is expected to significantly influence market dynamics by improving patient adherence and treatment outcomes
  • Startups are focusing on sustainability by developing eco-friendly products and utilizing recycled materials. While specific examples in the FMT sector are limited, the broader pharmaceutical industry is increasingly adopting sustainable practices, such as using biodegradable excipients and reducing carbon footprints in manufacturing processes.
  • Emerging startups are addressing niche markets by developing FMTs for specific therapeutic areas, such as pediatric or geriatric formulations. For example, SPI Pharma's Mannogem XL Opal is designed for fast-melt and chewable tablets, catering to the needs of patients who have difficulty swallowing traditional tablets.
Key Players Insights
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Amgen Inc.
  • Allergan plc
  • Aurobindo Pharma Ltd.
  • Hikma Pharmaceuticals plc
  • Sun Pharmaceutical Industries Ltd.
  • Strides Pharma Science Limited
  • Zydus Cadila

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2025 Coherent Market Insights Pvt Ltd. All Rights Reserved.